SYSteven M. Yip

Steven M. Yip

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Steven M. Yip has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Anil Kapoor

    Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada

    2 shared publications
  • Kim N. Chi

    BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada

    2 shared publications
  • Ajjai S. Alva

    Division of Hematology/Oncology Department of Internal Medicine University of Michigan Ann Arbor Michigan

    1 shared publication
  • Alan So

    Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada

    1 shared publication
  • Alex Wong

    Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

    1 shared publication
  • Alexander W. Wyatt

    Vancouver Prostate Centre Vancouver British Columbia Canada

    1 shared publication

Latest Publications

  • Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.

    by Luke Lavallee, Chris Morash, Fred Saad, Steven Yip, Anil Kapoor, Michael Paul Kolinsky, Frederic Pouliot, Elie Antebi, Darrel Drachenberg, Cristiano Ferrario, et al.

    252 Background: The management of patients with mCRPC has evolved since the introduction of androgen-receptor axis targeted agents (ARATs). The Genitourinary Research Consortium (GURC) initiated a prospective, phase 4, multicentre, non-interventional, longitudinal cohort study of Canadian men with advanced prostate cancer to determine real-world treatment patterns and outcomes. Methods: 25 sites across Canada participated in this study including patients managed by urologists, medical- and radiation-oncologists between 2018 to 2021. Baseline patient characteristics and mCRPC treatment patterns are reported here. Treatment patterns reviewed included time to second-line treatment use and time to progression or death. Results: 136 mCRPC patients were enrolled. Median age was 73 years (range 66 to 80) with 54 (40%) having a Gleason score of >8 at diagnosis. Median PSA at enrollment was 8.9 (2.4 to 25.1) ng/ml. At study entry, 90/132 (66%) patients with mCSPC and 42/132 (31%) patients nmCRPC had progressed to develop mCRPC. One hundred and twenty-one (89%) of patients in this cohort received first-line treatment for mCRPC, the most common was abiraterone acetate + prednisone in 67 (49%) and enzalutamide in 41 (30%), followed by docetaxel in 6 (4.4%), and Radium-223 in 5 (3.7%) patients. During the 25-month median follow-up period (range 6-28), 59 (49%) of the patients receiving first line mCRPC therapy had documented disease progression or death. At the time of last recorded follow-up, 37 (28%) patients who progressed received a second-line therapy for mCRPC. Median time to progression in this cohort was 21 months (95% CI: 15.2 - NE), with ARAT-to-ARAT being the most common sequencing pattern observed in 15 (39%) patients, followed by ARAT to chemotherapy in 14 (37%). Conclusions: In this real-world analysis of mCRPC patients, ARAT therapy was the preferred approach for first-line treatment intensification in over 108 (80%) patients. Despite evidence of poor response rates, ARAT-to-ARAT was the most common sequencing for second line therapy, followed by ARAT-to-chemotherapy treatment. Further analysis and follow-up will help define optimal mCRPC management, in real world setting.


  • Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer

    by Daniel H. Kwon, Jonathan Chou, Steven M. Yip, Melissa A. Reimers, Li Zhang, Francis Wright, Mallika S. Dhawan, Hala T. Borno, Arpita Desai, Rahul R. Aggarwal, et al.

    BACKGROUND: DNA damage repair mutations (DDRm) are common in patients with metastatic castration‐resistant prostate cancer (mCRPC). The optimal standard therapy for this population is not well described.METHODS: A multi‐institutional, retrospective study of patients with mCRPC and DDRm was conducted. Patient data, including systemic therapies and responses, were collected. The decline in prostate‐specific antigen ≥ 50% from baseline (PSA50) and overall survival (OS) from the treatment start were compared by mutation and treatment type. A multivariable Cox proportional hazards model for OS was created that controlled for DDRm, first‐line treatment received for mCRPC, and clinical factors.RESULTS: The most common DDRm observed among 149 men with mCRPC were BRCA1/2 (44%), CDK12 (32%), and ATM (15%). The majority received first‐line abiraterone (40%) or enzalutamide (30%). The PSA50 rate with first‐line abiraterone was lower for CDK12 (52%) than BRCA1/2 (89%; P = .02). After first‐line abiraterone or enzalutamide, the median OS was longest with second‐line carboplatin‐chemotherapy (38 months) in comparison with abiraterone or enzalutamide (33 months), docetaxel (17 months), or cabazitaxel (11 months; P = .02). PSA50 responses to carboplatin‐based chemotherapy were higher for BRCA1/2 (79%) than ATM (14%; P = .02) or CDK12 (38%; P = .08). In a multivariable analysis, neither the specific DDRm type nor the first‐line treatment was associated with improved OS.CONCLUSIONS: Responses to standard therapies were generally superior in patients with BRCA1/2 mutations and inferior in patients with ATM or CDK12 mutations. The DDRm type did not independently predict OS. After progression on first‐line abiraterone or enzalutamide, carboplatin‐based chemotherapy was associated with the longest OS. These findings may inform treatment discussions and clinical trial design and require prospective validation.


  • Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    by Steven M. Yip, Connor Wells, Raphael Moreira, Alex Wong, Sandy Srinivas, Benoit Beuselinck, Camillo Porta, Hao‐Wen Sim, D. Scott Ernst, Brian I. Rini, et al.

    BACKGROUND: To the authors' knowledge, outcomes and prognostic tools have yet to be clearly defined in patients with metastatic renal cell carcinoma (mRCC) who are treated with immuno‐oncology (IO) checkpoint inhibitors (programmed death‐ligand 1 [PD‐L1] inhibitors). In the current study, the authors aimed to establish IO efficacy benchmarks in patients with mRCC and update patient outcomes in each International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic class. METHODS: A retrospective analysis was performed using the IMDC database with data from 38 centers. It included patients with mRCC who were treated with ≥1 line of IO. Overall response rates (ORRs), duration of treatment (DOT), and overall survival (OS) were calculated. Patients were stratified using IMDC prognostic factors. RESULTS: A total of 687 patients (90% with clear cell and 10% with non‐clear cell) were included. The ORR was 27% in evaluable patients (461 patients). In patients treated with first‐line nivolumab and ipilimumab (49 patients), the combination of PD‐L1 inhibitor and vascular endothelial growth factor inhibitor (72 patients), and PD‐L1 inhibitor (51 patients), the ORR was 31%, 39%, and 40%, respectively, and the median DOT was 8.3 months, 14.7 months, and 8.3 months, respectively. The ORR for second‐line, third‐line, and fourth‐line nivolumab was 22%, 24%, and 26%, respectively. The median DOT was 5.7 months, 6.2 months, and 8.3 months, respectively, in the second‐line, third‐line, and fourth‐line settings. When segregated into IMDC favorable‐risk, intermediate‐risk, and poor‐risk groups, the median OS rates for the first‐line, second‐line, third‐line, and fourth‐line treatment settings were not reached (NR), NR, and NR, respectively ( P = .163); NR, 26.7 months, and 7.4 months, respectively ( P < 0. 0001); 36.1 months, 28.2 months, and 11.1 months, respectively ( P = .016); and NR, NR, and 6.7 months, respectively ( P = .047). CONCLUSIONS: The ORR was not found to deteriorate from the first‐line to the fourth‐line of IO therapy. In the second line through fourth line, the IMDC criteria appropriately stratified patients into favorable‐risk, intermediate‐risk, and poor‐risk groups for OS.